Dashboard
Manage Tickers

CAPRCAPRICOR THERAPEUTICS, INC.

Nasdaq capricor.com


$ 4.65 $ -0.15 (-3.13 %)    

Tuesday, 25-Jun-2024 15:59:55 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 479.35 $ 5.42 (1.14 %)
DIA $ 391.06 $ -2.96 (-0.75 %)
SPY $ 544.78 $ 2.09 (0.39 %)
TLT $ 94.49 $ 0.16 (0.17 %)
GLD $ 214.55 $ -1.07 (-0.5 %)
$ 4.64
$ 4.90
$ 0.00 x 0
$ 0.00 x 0
$ 4.58 - $ 4.91
$ 2.68 - $ 8.22
505,494
na
145.49M
$ 0.73
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-14-2024 03-31-2024 10-Q
2 03-11-2024 12-31-2023 10-K
3 11-14-2023 09-30-2023 10-Q
4 08-08-2023 06-30-2023 10-Q
5 05-12-2023 03-31-2023 10-Q
6 03-17-2023 12-31-2022 10-K
7 11-10-2022 09-30-2022 10-Q
8 08-12-2022 06-30-2022 10-Q
9 05-11-2022 03-31-2022 10-Q
10 03-11-2022 12-31-2021 10-K
11 11-11-2021 09-30-2021 10-Q
12 08-13-2021 06-30-2021 10-Q
13 05-14-2021 03-31-2021 10-Q
14 03-15-2021 12-31-2020 10-K
15 11-13-2020 09-30-2020 10-Q
16 08-10-2020 06-30-2020 10-Q
17 05-15-2020 03-31-2020 10-Q
18 03-27-2020 12-31-2019 10-K
19 11-08-2019 09-30-2019 10-Q
20 08-08-2019 06-30-2019 10-Q
21 05-14-2019 03-31-2019 10-Q
22 03-29-2019 12-31-2018 10-K
23 11-14-2018 09-30-2018 10-Q
24 08-13-2018 06-30-2018 10-Q
25 05-14-2018 03-31-2018 10-Q
26 03-22-2018 12-31-2017 10-K
27 11-14-2017 09-30-2017 10-Q
28 08-14-2017 06-30-2017 10-Q
29 05-15-2017 03-31-2017 10-Q
30 03-16-2017 12-31-2016 10-K
31 11-14-2016 09-30-2016 10-Q
32 08-15-2016 06-30-2016 10-Q
33 05-13-2016 03-31-2016 10-Q
34 03-30-2016 12-31-2015 10-K
35 11-13-2015 09-30-2015 10-Q
36 08-14-2015 06-30-2015 10-Q
37 05-13-2015 03-31-2015 10-Q
38 03-16-2015 12-31-2014 10-K
39 11-14-2014 09-30-2014 10-Q
40 08-14-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

capricor-therapeutics-announces-the-fda-has-scheduled-pre-bla-meeting-with-the-company-for-the-treatment-of-duchenne-muscular-dystrophy
Capricor Therapeutics Announces The FDA Ha...
06/25/2024 12:37:48

Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for ...

capricor-therapeutics-files-for-mixed-shelf-offering-of-up-to-150m
Capricor Therapeutics Files For Mixed Shel...
06/14/2024 20:34:05

-SEC Filing

12-health-care-stocks-moving-in-tuesdays-after-market-session
12 Health Care Stocks Moving In Tuesday's ...
06/11/2024 20:31:35

whats-going-on-with-capricor-therapeutics-stock-tuesday
What's Going On With Capricor Therapeutics...
06/11/2024 19:27:37

Capricor Therapeutics announced successful completion of a Type-B meeting with the U.S. Food and Drug Administration (FDA).

capricor-therapeutics-completes-type-b-meeting-with-fda-for-cap-1002-program-for-duchenne-muscular-dystrophy-with-aim-to-expedite-bla-pathway
Capricor Therapeutics Completes Type-B Mee...
06/11/2024 13:31:19

--FDA Grants Pre-BLA Meeting Request and Rolling BLA Submission after Review of HOPE-2 and HOPE-2 OLE 3-Year Results--

whats-going-on-with-capricor-therapeutics-stock-tuesday
What's Going On With Capricor Therapeutics...
06/04/2024 17:12:51

Capricor Therapeutics, Inc. (NASDAQ: CAPR) is trading higher Tuesday after the company announced three-year results from the on...

capricor-therapeutics-reports-3-year-efficacy-results-from-hope-2-open-label-extension-study-of-cap-1002-in-dmd
Capricor Therapeutics Reports 3-Year Effic...
06/04/2024 13:05:39

--Results in Performance of the Upper Limb (PUL 2.0) Continue to Show Benefits in Skeletal Muscle Function After 3 Years of CAP...

oppenheimer-initiates-coverage-on-capricor-therapeutics-with-outperform-rating-announces-price-target-of-14
Oppenheimer Initiates Coverage On Capricor...
05/17/2024 09:37:55

Oppenheimer analyst Leland Gershell initiates coverage on Capricor Therapeutics (NASDAQ:CAPR) with a Outperform rating and a...

expert-ratings-for-capricor-therapeutics
Expert Ratings For Capricor Therapeutics
05/14/2024 19:01:00

ladenburg-thalmann-maintains-buy-on-capricor-therapeutics-raises-price-target-to-25
Ladenburg Thalmann Maintains Buy on Capric...
05/14/2024 18:23:48

Ladenburg Thalmann analyst Aydin Huseynov maintains Capricor Therapeutics (NASDAQ:CAPR) with a Buy and raises the price targ...

cantor-fitzgerald-reiterates-overweight-on-capricor-therapeutics-maintains-8-price-target
Cantor Fitzgerald Reiterates Overweight on...
05/14/2024 12:58:47

Cantor Fitzgerald analyst Kristen Kluska reiterates Capricor Therapeutics (NASDAQ:CAPR) with a Overweight and maintains $8 p...

hc-wainwright--co-reiterates-buy-on-capricor-therapeutics-maintains-40-price-target
HC Wainwright & Co. Reiterates Buy on Capr...
05/14/2024 11:31:35

HC Wainwright & Co. analyst Joseph Pantginis reiterates Capricor Therapeutics (NASDAQ:CAPR) with a Buy and maintains $40...

capricor-therapeutics-expects-available-cash--equivalents-to-be-sufficient-to-cover-anticipated-expenses-and-capital-requirements-into-q1-of-2025
Capricor Therapeutics Expects Available Ca...
05/13/2024 20:20:40

capricor-therapeutics-q1-2024-gaap-eps-031-misses-011-estimate-sales-4906m-miss-9700m-estimate
Capricor Therapeutics Q1 2024 GAAP EPS $(0...
05/13/2024 20:16:14

Capricor Therapeutics (NASDAQ:CAPR) reported quarterly losses of $(0.31) per share which missed the analyst consensus estimate ...

capricor-therapeutics-to-present-exosome-platform-updates-at-asgct-27th-annual-meeting-preclinical-findings-show-exosome-based-therapeutic-approach-for-the-treatment-of-arginase-1-deficiency
Capricor Therapeutics To Present Exosome P...
05/09/2024 13:39:03

-Preclinical findings show exosome-based therapeutic approach for the treatment of arginase-1 deficiency (ARG1-D)- -Presentatio...

hc-wainwright--co-reiterates-buy-on-capricor-therapeutics-maintains-40-price-target
HC Wainwright & Co. Reiterates Buy on Capr...
04/25/2024 11:25:38

HC Wainwright & Co. analyst Joseph Pantginis reiterates Capricor Therapeutics (NASDAQ:CAPR) with a Buy and maintains $40...

capricor-therapeutics-announces-type-b-meeting-with-fda-for-cap-1002-program-for-duchenne-muscular-dystrophy-fda-feedback-supports-requests-for-pre-bla-meeting-and-subsequent-rolling-bla-submission-following-upcoming-q2-type-b-fda-meeting
Capricor Therapeutics Announces Type-B Mee...
04/24/2024 13:04:01

hc-wainwright--co-reiterates-buy-on-capricor-therapeutics-maintains-40-price-target
HC Wainwright & Co. Reiterates Buy on Capr...
03/01/2024 11:51:19

HC Wainwright & Co. analyst Joseph Pantginis reiterates Capricor Therapeutics (NASDAQ:CAPR) with a Buy and maintains $40...

recap-capricor-therapeutics-q4-earnings
Recap: Capricor Therapeutics Q4 Earnings
02/29/2024 21:30:15

capricor-therapeutics-q4-2023-gaap-eps-0020-beats-0200-estimate-sales-12088m-beat-10600m-estimate
Capricor Therapeutics Q4 2023 GAAP EPS $(0...
02/29/2024 21:27:20

Capricor Therapeutics (NASDAQ:CAPR) reported quarterly losses of $(0.020) per share which beat the analyst consensus estimate o...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

06/28/2024 Malibu Boats, Inc. (MBUU)
07/01/2024 Globe Life Inc. f/k/a Torchmark Corporation (GL)
07/01/2024 Equinix, Inc. (EQIX)
07/02/2024 Intel Corporation (INTC)
07/05/2024 AXT, Inc. (AXTI)
07/05/2024 Altimmune, Inc. (ALT)
07/09/2024 Li Auto Inc. (LI)
07/12/2024 Inari Medical, Inc. (NARI)
07/12/2024 Sprout Social, Inc. (SPT)
07/15/2024 UnitedHealth Group Inc. (UNH)

NEW CASE INVESTIGATION

Ooma Inc (OOMA) AnaptysBio Inc (ANAB)